<div id="readability-page-1"><div><h3>Key Insights</h3><ul> <li> Inhibikase Therapeutics' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public </li> <li> 51% of the business is held by the top 11 shareholders </li> <li>  Institutional ownership in Inhibikase Therapeutics is 30% </li> </ul><p>Trump has pledged to &#34;unleash&#34; American oil and gas and these 15 US stocks have developments that are poised to benefit.</p><p> Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups.  With 39% stake, individual investors possess the maximum shares in the company.   In other words, the group stands to gain the most (or lose the most) from their investment into the company. </p><p> While individual investors were the group that reaped the most benefits after last week’s 11% price gain, institutions also received a 30% cut.     </p><p> In the chart below, we zoom in on the different ownership groups of Inhibikase Therapeutics. </p><p><span> Check out our latest analysis for Inhibikase Therapeutics </span></p><figure><img height="245" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-ownership-breakdown-1-dark-2/1765881740832"/><figcaption>NasdaqCM:IKT Ownership Breakdown December 16th 2025</figcaption></figure> <h2>What Does The Institutional Ownership Tell Us About Inhibikase Therapeutics?</h2><p> Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. </p> <p> We can see that Inhibikase Therapeutics does have institutional investors; and they hold a good portion of the company's stock.  This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does.  When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Inhibikase Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story. </p><figure><img height="1048" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1642" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/113910012-earnings-and-revenue-growth-1-dark-2/1765881742801"/><figcaption>NasdaqCM:IKT Earnings and Revenue Growth December 16th 2025</figcaption></figure> <p> It looks like hedge funds own 11% of Inhibikase Therapeutics shares.  That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher.      Sands Capital Ventures, LLC is currently the largest shareholder, with 11% of shares outstanding.       In comparison, the second and third largest shareholders hold about 5.4% and 5.2% of the stock.   </p> <p> Looking at the shareholder registry, we can see that 51% of the ownership is controlled by the top 11 shareholders, meaning that no single shareholder has a majority interest in the ownership.  </p> <p> Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments.   There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.  </p><h2>Insider Ownership Of Inhibikase Therapeutics</h2><p> The definition of an insider can differ slightly between different countries, but members of the board of directors always count.  Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. </p><p> Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances. </p> <p> Our most recent data indicates that insiders own some shares in Inhibikase Therapeutics, Inc..   As individuals, the insiders collectively own US$7.9m worth of the US$190m company.   It is good to see some investment by insiders, but we usually like to see higher insider holdings. It might be worth checking if those insiders have been buying.  </p> <h2>General Public Ownership</h2><p> The general public-- including retail investors -- own 39% stake in the company, and hence can't easily be ignored.   This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. </p> <h2>Private Equity Ownership</h2><p> With an ownership of 11%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation.  Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.  </p> <h2>Private Company Ownership</h2><p> Our data indicates that Private Companies hold 5.0%, of the company's shares.   It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.  </p> <h2>Next Steps:</h2><p> It's always worth thinking about the different groups who own shares in a company. But to understand Inhibikase Therapeutics better, we need to consider many other factors.    For instance, we've identified  <strong> 4 warning signs for Inhibikase Therapeutics</strong> (3 are potentially serious)  that you should be aware of.   </p> <p> But ultimately <strong> it is the future</strong>, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. </p> <p><small>NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.</small></p><div><p>Mobile Infrastructure for Defense and Disaster</p><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p><p>Get the investor briefing before the next round of contracts</p><p><span>Sponsored On Behalf of CiTech</span></p></div></div></div>

<p>Inhibikase Therapeutics (NASDAQ:IKT) saw an 11% stock price increase last week, benefiting individual investors the most, who hold 39% of shares. Institutions own 30%, while hedge funds and private equity firms each hold 11%. The top 11 shareholders control 51% of the company. Insider ownership is valued at $7.9m. The general public's stake is significant but not enough to influence company policy alone.</p>

Simplywall

Inhibikase Therapeutics

While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most